Strontium ranelate, > = 98%( HPLC)

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Strontium ranelate is a dual action bone agent (DABA). It inhibits bone resorption and stimulates bone formation, inhibiting osteoclast differentiation while activating gene expression in osteoblasts. While its exact mechanism of action is unknown, one hypothesis is that both anabolic and anti-catabolic activities may involve antagonizing nuclear factor-KB (NF-KB) activation in bone cells. Strontium ranelate has been shown to inhibit the receptor activator of NF-KB ligand (RANKL)-induced nuclear translocation of NF-KB and activator protein-1. Strontium ranelate has been used clinically for the treatment of osteoporosis and a recent multinational study indicates the drug can also be used to treat osteoarthritis.

Features and Benefits

This compound is featured on the Cytokine Receptors (Tumor Necrosis Receptor Family) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

10, 50 mg in glass bottle